Skip to main content
. 2022 Jan 22;10(2):234. doi: 10.3390/biomedicines10020234

Figure 4.

Figure 4

SLC27A5 regulates the expression of tyrosine-metabolizing enzymes. (A,B) The overlapping analysis for co-expressed genes of five tyrosine-metabolizing enzymes in HCC patients. (C) Representative IHC staining of SLC27A5, HGD, GSTZ1 and FAH in HCC from HPA database. (D–F) The SLC27A5 mRNA expression levels between tumor and normal tissues in patients with HCC in the GEO and TCGA database. (G) The SLC27A5 mRNA expression levels between different grades of tumor and normal tissues in patients with HCC in TGCA database. (H) Overall survival of patients with HCC grouped by SLC27A5 expression through the Kaplan-Meier Plotter online analysis tool. (I) GSEA pathway enrichment analyses of SLC27A5 expression signature in patients with HCC from the TCGA-LIHC datasets. (J) The core-enriched signaling pathways in high SLC27A5 level and low level groups. (K,L) The binding motif of transcription factor NRF2 and tyrosine-metabolizing enzyme promoter. The p values were determined by the two-tailed t-tests. *** p < 0.001.